NCT03559582 is a clinical trial in Tuberculosis, sponsored by University of Virginia.

Who is sponsoring NCT03559582?

NCT03559582 is sponsored by University of Virginia.

What condition does NCT03559582 study?

NCT03559582 studies Tuberculosis.

Is NCT03559582 still recruiting?

NCT03559582 is currently completed. Last updated 9 March 2022.

Last reviewed 2022-03-09 · How we verify

NCT03559582

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diagnostics and Pharmacotherapy for Severe Forms of TB (DMID 15-0100)

Completed Last updated 9 March 2022

What this trial tests

trial in Tuberculosis in 478 participants. Completed in 31 January 2021.

Timeline

28 April 2016

Primary endpoint
31 July 2020

31 January 2021

Quick facts

Lead sponsor	University of Virginia
Status	Completed
Study type	OBSERVATIONAL
Enrollment	478
Start date	28 April 2016
Primary completion	31 July 2020
Estimated completion	31 January 2021

Conditions studied

Tuberculosis — all drugs for Tuberculosis →

Sponsor

University of Virginia

Who can join

Eligibility, any sex, with Tuberculosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Major Research Aim: To study novel molecular diagnostics and the pharmacokinetic variability among a spectrum of TB disease states, including severe forms of TB like disseminated TB, TB meningitis and drug resistant TB, among adults and children from multiple international sites.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

A systematic review and meta-analysis of first-line tuberculosis drug concentrations and treatment outcomes.
Perumal R, Naidoo K, Naidoo A, Ramachandran G, et al · · 2020 · cited 23× · PMID 32005307 · DOI 10.5588/ijtld.19.0025
Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection.
Al-Shaer MH, Alghamdi WA, Alsultan A, An G, et al · · 2019 · cited 19× · PMID 31061152 · DOI 10.1128/aac.00279-19
Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania.
Mohamed S, Mvungi HC, Sariko M, Rao P, et al · · 2021 · cited 17× · PMID 33675664 · DOI 10.1093/jac/dkab057
Determination of Rifampin Concentrations by Urine Colorimetry and Mobile Phone Readout for Personalized Dosing in Tuberculosis Treatment.
Szipszky C, Van Aartsen D, Criddle S, Rao P, et al · · 2021 · cited 16× · PMID 32170944 · DOI 10.1093/jpids/piaa024
Population Pharmacokinetics and Significant Under-Dosing of Anti-Tuberculosis Medications in People with HIV and Critical Illness.
Rao PS, Moore CC, Mbonde AA, Nuwagira E, et al · · 2021 · cited 15× · PMID 34207312 · DOI 10.3390/antibiotics10060739
Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study.
Heysell SK, Mpagama SG, Ogarkov OB, Conaway M, et al · · 2023 · cited 11× · PMID 35731948 · DOI 10.1093/cid/ciac511
Pharmacogenetic testing for NAT2 genotypes in a Tanzanian population across the lifespan to guide future personalized isoniazid dosing.
Masiphephethu MV, Sariko M, Walongo T, Maro A, et al · · 2022 · cited 10× · PMID 35961094 · DOI 10.1016/j.tube.2022.102246
Enteropathogen spectrum and effect on antimycobacterial pharmacokinetics among children with tuberculosis in rural Tanzania: a prospective cohort study.
Van Aartsen D, Justine M, Mduma E, Mpagama SG, et al · · 2022 · cited 7× · PMID 35659902 · DOI 10.1016/s2666-5247(21)00308-6

Verify or expand the search:

Other recruiting trials for Tuberculosis

Currently open trials in the same condition.

NCT05917210 — Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda · NA · recruiting
NCT07170735 — Quantitative Measurement of Plasma and Urine MTB Cell-free DNA Level · recruiting
NCT07484490 — Effects of the Active Cycle of Breathing Technique With and Without Balloon Blowing Therapy in Tuberculosis · NA · recruiting
NCT06318416 — Precision Rifampin Trial for Personalized Dosing · Phase 1 · recruiting
NCT07170800 — A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets · Phase 2 · recruiting

Other University of Virginia trials

Trials by the same sponsor.

NCT05880355 — Multimodality Cardiovascular Imaging for the Translation of Therapies for Vascular Activation After MI · EARLY_PHASE1 · not yet recruiting
NCT07405645 — Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy · NA · recruiting
NCT07146685 — Effect of Local Anesthetic Concentration on Rebound Pain: A Randomized Control Study · Phase 4 · not yet recruiting
NCT07298941 — Resilience Enhancement Following Sleep Treatment · Phase 2 · recruiting
NCT07036315 — Meaning in Music-Based Pain Modulation · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03559582 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Virginia
Last refreshed: 9 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03559582.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing